neurogenin 2

Neurog2 (Neurogenin 2) is a basic helix-loop-helix (bHLH) transcription factor that serves as a master regulator of neurogenesis during development. In therapeutic research, Neurog2 is being explored as a gene therapy candidate for the treatment of glioblastoma multiforme (GBM). The approach involves the viral delivery (e.g., via retroviral or adenoviral vectors) of the Neurog2 gene into glioblastoma cells to induce "trans-differentiation." This process reprograms the rapidly proliferating, undifferentiated cancer cells into mature, non-proliferating neurons, such as glutamatergic neurons. By forcing the cells to exit the cell cycle and adopt a neuronal fate, Neurog2-based therapy aims to inhibit tumor progression and reduce the infiltrative capacity of glioblastoma. Preclinical studies, including those from Pennsylvania State University, have demonstrated that Neurog2 overexpression can effectively convert human GBM cells into functional neuron-like cells expressing markers such as MAP2 and NeuN.

Other names

Neurogenin-2Neurogenin2Neurogenin 2